AU2022331233A1 - Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action - Google Patents

Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action Download PDF

Info

Publication number
AU2022331233A1
AU2022331233A1 AU2022331233A AU2022331233A AU2022331233A1 AU 2022331233 A1 AU2022331233 A1 AU 2022331233A1 AU 2022331233 A AU2022331233 A AU 2022331233A AU 2022331233 A AU2022331233 A AU 2022331233A AU 2022331233 A1 AU2022331233 A1 AU 2022331233A1
Authority
AU
Australia
Prior art keywords
substituent group
hydrogen
optionally substituted
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022331233A
Other languages
English (en)
Inventor
Masato Kaneda
Issei Kato
Masayoshi Miyagawa
Ryota Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of AU2022331233A1 publication Critical patent/AU2022331233A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2022331233A 2021-08-20 2022-08-19 Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action Pending AU2022331233A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021134801 2021-08-20
JP2021-134801 2021-08-20
PCT/JP2022/031308 WO2023022216A1 (ja) 2021-08-20 2022-08-19 ウイルス増殖抑制作用を有するヌクレオシド誘導体及びそれらのプロドラッグ

Publications (1)

Publication Number Publication Date
AU2022331233A1 true AU2022331233A1 (en) 2024-02-29

Family

ID=85240607

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022331233A Pending AU2022331233A1 (en) 2021-08-20 2022-08-19 Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action

Country Status (12)

Country Link
US (1) US20250170155A1 (https=)
EP (1) EP4389750A4 (https=)
JP (1) JPWO2023022216A1 (https=)
KR (1) KR20240050362A (https=)
CN (1) CN118119624A (https=)
AU (1) AU2022331233A1 (https=)
CA (1) CA3229752A1 (https=)
CO (1) CO2024003018A2 (https=)
IL (1) IL310854A (https=)
MX (1) MX2024002116A (https=)
PE (1) PE20240654A1 (https=)
WO (1) WO2023022216A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300412A (en) 2020-08-24 2023-04-01 Gilead Sciences Inc Phospholipid compounds and their uses
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3277623D1 (en) 1981-07-31 1987-12-17 Sloan Kettering Inst Cancer Anti-leukemic beta-glycosyl c-nucleosides
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US7109331B2 (en) 2000-08-29 2006-09-19 Industrial Research Limited 5H-pyrrolo[3,2-d]pyrimidine nucleoside metabolism inhibitors
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US20040063658A1 (en) 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
CA2568379A1 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
US7560434B2 (en) 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
AU2005302448B2 (en) 2004-10-29 2012-07-19 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
WO2007069924A1 (en) 2005-12-15 2007-06-21 Industrial Research Limited Deazapurine analogs of 4'-aza-l-nucleosides
MX2009007333A (es) * 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
HRP20120914T1 (hr) 2007-05-10 2012-12-31 Biocryst Pharmaceuticals, Inc. Spojevi tetrahidrofuro[3,4-d]dioksolana, namijenjeni upotrebi u lijeäśenju virusnih infekcija i raka
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
TW201305185A (zh) 2010-09-13 2013-02-01 吉李德科學股份有限公司 用於抗病毒治療之２’－氟取代之碳－核苷類似物
US9290501B2 (en) 2010-11-29 2016-03-22 Albert Einstein College Of Medicine, Inc. Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase
MD4496C1 (ro) * 2012-03-13 2018-02-28 Gilead Sciences, Inc. Analogi carba-nucleozidici 2'-substituiţi pentru tratament antiviral
AR090699A1 (es) 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
JP2016504284A (ja) * 2012-11-16 2016-02-12 バイオクリスト ファーマスーティカルズ，インコーポレイテッドＢｉｏｃｒｙｓｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 抗ウイルス性アザ糖を含有するヌクレオシド
CA2911424C (en) 2013-05-14 2021-11-30 Biocryst Pharmaceuticals, Inc. Anti-influenza imino-ribose pyrrolopyrimidine derivatives
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
CN107108683A (zh) 2014-10-31 2017-08-29 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的2’,2’‑二卤代核苷类似物
CN110678473A (zh) 2017-04-25 2020-01-10 大原药品工业株式会社 核苷类抗癌药或抗病毒药的5’位二苄基单磷酸酯衍生物
WO2018230479A1 (ja) 2017-06-13 2018-12-20 大原薬品工業株式会社 ヌクレオシド系抗がん剤又は抗ウィルス剤の５'位シリルエーテル誘導体
CA3075950A1 (en) * 2017-09-18 2019-03-21 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA3126348A1 (en) 2018-01-12 2020-07-18 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2021040356A1 (en) 2019-08-23 2021-03-04 Kainos Medicine, Inc. C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition
CN112778310B (zh) 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN112062800B (zh) 2020-09-02 2022-11-18 广东东阳光药业有限公司 核苷化合物的氨基磷酸酯衍生物及其用途
CN112010916B (zh) 2020-09-09 2022-12-27 广东东阳光药业有限公司 核苷化合物的氨基磷酸酯衍生物及其用途

Also Published As

Publication number Publication date
KR20240050362A (ko) 2024-04-18
WO2023022216A1 (ja) 2023-02-23
MX2024002116A (es) 2024-03-06
EP4389750A4 (en) 2025-10-01
CA3229752A1 (en) 2023-02-23
EP4389750A1 (en) 2024-06-26
JPWO2023022216A1 (https=) 2023-02-23
IL310854A (en) 2024-04-01
US20250170155A1 (en) 2025-05-29
CN118119624A (zh) 2024-05-31
PE20240654A1 (es) 2024-04-04
CO2024003018A2 (es) 2024-03-18

Similar Documents

Publication Publication Date Title
AU2022331233A1 (en) Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action
EP4185569B1 (en) Methods and compositions for targeting pd-l1
AU2011243597B2 (en) Novel hydroxamic acid derivative
WO2020104335A1 (en) Alpha-d-galactoside inhibitors of galectins
AU2009221770A1 (en) Antiviral therapeutic agents
AU2016254700A1 (en) RSV antiviral pyrazolo- and triazolo-pyrimidine compounds
US11236086B2 (en) Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
CA3104088A1 (en) Ectonucleotidase inhibitors and methods of use thereof
US12508264B2 (en) Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof
EP4242212A2 (en) Sting modulator compounds with sulfamate linkages, and methods of making and using
WO2021214136A1 (en) Rsv inhibiting 3-substituted quinoline and cinnoline derivatives
CN106589055A (zh) 取代的细胞酰二肽类化合物及其制备方法和用途
EP3759113B1 (en) 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
WO2022092141A1 (ja) 抗ウイルス活性を有するアミド誘導体
RU2649575C1 (ru) Азаиндольное производное
CN110903289B (zh) 嘌呤-氨甲基-吡啶酮衍生物及其制备方法和用途
AU2016302302B2 (en) Pyrrolo[2,3-d]pyrimidine compound or salt thereof
EP3543238A1 (en) Nucleoside derivative having physical activities including anti-viral activity
TW202517253A (zh) Cdk2抑制劑及其用途
BR112023007766B1 (pt) Derivado de amida que apresenta atividade antiviral, seus usos e sua composição farmacêutica
HK40074766B (en) Macrocyclic compounds as sting agonists and methods and uses thereof
HK40042824B (en) 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
HK40042824A (en) 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
BR112018001695B1 (pt) COMPOSTO PIRROLO[2,3-d]PIRIMIDINA, INIBIDOR DE JAK3, COMPOSIÇÃO FARMACÊUTICA, AGENTE, USOS DO DITO COMPOSTO E MÉTODO PRA PRODUÇÃO DO MESMO